CD70 As an Actionable Immunotherapeutic Target in Recurrent Glioblastoma
bioRxiv preprint doi: https://doi.org/10.1101/2021.06.02.446670; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Hitting more birds with one stone: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma 1* 2* 1 2 1 2 Seyfrid M , Maich W , Shaikh MV ,Tatari N , Upreti D , Piyasena D , Subapanditha M1, Savage N2, McKenna D1, Kuhlmann L 3, Khoo A3, Salim SK2, Bassey-Archibong B1, Gwynne W1, Chokshi C 2, Brown K4, Murtaza N2, Bakhshinyan D2, Vora P1, Venugopal C1, Moffat J4, Singh SK1,2. *These authors made equal contributions to this paper Departments of 1Surgery, 2Biochemistry and Biomedical Sciences, Faculty of Health Sciences, McMaster University, 1200 Main Street West, Hamilton, Ontario, L8N 3Z5, Canada 3Princess Margaret’s Hospital, Toronto, Ontario, M5S 3E1, Canada 4Donnelly Centre, Department of Molecular Genetics, University of Toronto, Ontario, Canada RUNNING TITLE CD70 as an immunotherapeutic for recurrent GBM KEYWORDS: Glioblastoma, CD70, Immunotherapy, CAR-T CONFLICTS OF INTEREST: This work was partly funded by Longbow Therapeutics (company no longer in existence) 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.06.02.446670; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
[Show full text]